Name: Dabrafenib
Synonyms: Tafinlar, GSK2118436
MECHANISM OF ACTION
Dabrafenib is a selective kinase inhibitor that is active against several mutated forms of BRAF kinase including BRAF V600E, BRAF V600K, and BRAF V600D. 1 BRAF kinases are part of the mitogen-activated protein kinase (MAPK) pathway, which promotes cellular proliferation. Oncogenic mutations leading to activation of BRAF occur in a variety of tumor types, including cutaneous melanoma (50% of cases), papillary thyroid cancer (46% of cases), borderline ovarian tumors (34% of cases), and hairy cell leukemia (100% of cases). 2 In cutaneous melanoma, the activating mutation in the BRAF gene is V600E in 70% to 95% of cases and V600K in 5% to 30% of cases. Mutant BRAF predicts a poor prognosis in metastatic melanoma. 3 
PHARMACOKINETICS
Following oral administration of 150 mg every 12 hours, the median time to peak plasma concentration (T max ) is 2 hours 1,2,4 and the mean absolute bioavailability is 95%. 1 The geometric mean area under the plasma concentration-time curve (AUC) is 2619 ng•h/mL; the mean maximum plasma concentration (C max ) is 806 ng/mL. 2 Administration of dabrafenib with a high-fat meal causes a decrease in C max of 51%, a decrease in AUC of 31%, and an increase in T max to 3.6 hours compared to fasting state administration. 1 Dabrafenib is 99.7% protein bound, with an apparent volume of distribution (V d ) of 70.3 L. Dabrafenib is primarily metabolized by CYP2C8 and CYP3A4 to hydroxy-dabrafenib, probably an active metabolite, which is further oxidized by CYP3A4 to carboxy-dabrafenib, which is eliminated in bile and urine. 1 The mean terminal half life (t1 2 ) is 5.2 to 8 hours, 1,2 and the apparent clearance (CL) is 17 L/h following 14 days of twicedaily dosing. 1 Radioactive dose testing reveals that 71% of dabrafenib is eliminated in the feces and 23% in the urine. 1 Selected therapeutic regimens of dabrafenib appear in Table 1 
MECHANISM OF ACTION
Trametinib reversibly and selectively inhibits the activation of mitogen-activated extracellular signal regulated kinase (MEK) 1 and MEK2 and inhibits their kinase activity. 6, 7 MEK1 and MEK2 are downstream from BRAF in the MAPK pathway. 6 
PHARMACOKINETICS
Trametinib has a T max of 1.5 hours 6,8 and a mean absolute bioavailability of 72% following a single 2 mg oral dose. 6 With 2 mg once-daily dosing, the mean C max is 22.2 ng/mL and AUC is 370 ng•h/mL. 8 Administration of trametinib with a high-fat meal decreased AUC by 24% and C max by 70% and prolonged T max out to 5.5 hours compared to fasting state administration. 6 Trametinib is 97% protein bound and has an apparent V d of 214 L. 6 Metabolism is primarily by deacetylation, monooxygenation, and glucuronidation, with 80% of a radioactive dose recovered in the feces and less than 20% recovered in the urine. 6 T1 2 is 3.8 to 4.8 days, and CL is 4.9 L/h. 6, 8 Selected therapeutic regimens of trametinib appear in Table 2 .
PREPARATION
A. Follow institutional policies for preparation of hazardous medications when dispensing trametinib. Note: PO 5 oral. a Conforms to dosing information listed in the manufacturer's labeling.
